3.84
+0.05(+1.32%)
Currency In USD
| Previous Close | 3.79 |
| Open | 3.83 |
| Day High | 3.95 |
| Day Low | 3.71 |
| 52-Week High | 6.6 |
| 52-Week Low | 1 |
| Volume | 174,985 |
| Average Volume | 355,701 |
| Market Cap | 36.7M |
| PE | -2.46 |
| EPS | -1.56 |
| Moving Average 50 Days | 3.97 |
| Moving Average 200 Days | 2.91 |
| Change | 0.05 |
If you invested $1000 in SAB Biotherapeutics, Inc. (SABS) since IPO date, it would be worth $37.78 as of March 09, 2026 at a share price of $3.835. Whereas If you bought $1000 worth of SAB Biotherapeutics, Inc. (SABS) shares 3 years ago, it would be worth $661.21 as of March 09, 2026 at a share price of $3.835.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
SAB BIO Reports Full Year 2025 Financial Results and Business Highlights
GlobeNewswire Inc.
3 hours ago
Advanced SAB -142 into registrational Phase 2b SAFEGUARD study with multiple patients dosed; enrollment ongoing and on track to complete enrollment by end of 2026 with topline data expected in 2H 2027 Reported Phase 1 clinical data, including healthy
SAB BIO Strengthens Board of Directors with Appointment of New Chair and New Director
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
David Zaccardelli, Pharm.D. joins Board as Chair Rita Jain, M.D., joins Board as an Independent Director MIAMI, Jan. 07, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a full
SAB BIO to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today annou